help button home button Endocrine Society Molecular Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on March 31, 2005
Molecular Endocrinology, doi:10.1210/me.2005-0014
A more recent version of this article appeared on June 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
19/6/1529    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wan, W.
Right arrow Articles by Privalsky, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wan, W.
Right arrow Articles by Privalsky, M. L.

Submitted on January 7, 2005
Accepted on March 23, 2005

Pituitary resistance to thyroid hormone (RTH)-syndrome is associated with T3 receptor mutants that selectively impair {beta}2 isoform function

Wei Wan, Behnom Farboud, and Martin L. Privalsky*

Section of Microbiology, Division of Biological Sciences, University of California at Davis

* To whom correspondence should be addressed. E-mail: mlprivalsky{at}ucdavis.edu.

Resistance to thyroid hormone (RTH)-syndrome is an inherited inability to respond appropriately to T3 hormone. In generalized RTH, the T3 response of both the pituitary and periphery is disrupted. In pituitary (or central) RTH the ability of the pituitary to sense (and down-regulate) elevated T3 is selectively impaired, whereas the periphery remains relatively T3 responsive, resulting in peripheral thyrotoxicity. Both forms of disease are linked to mutations in thyroid hormone receptor (TR)-{beta}. TR{beta} is expressed by alternate mRNA splicing as two isoforms: TR{beta}2, found primarily in the pituitary/hypothalamus, and TR{beta}1, expressed broadly in many tissues. We report here that the wild-type TR{beta}2 isoform displays an enhanced T3 response relative to the TR{beta}1 isoform. Mutations associated with generalized RTH (P453S, G345S) impair both TR{beta}2 and TR{beta}1 function proportionally, whereas mutations associated with pituitary-specific RTH (R338L, R338W, R429Q) disproportionately disrupt TR{beta}2 function. We propose that in the normal organism, and in generalized RTH, TR{beta}2 in the pituitary can sense rising T3 levels in advance of TR{beta}1 in the periphery, preventing thyrotoxicity. In contrast, the TR{beta} mutations associated with pituitary RTH disproportionately disrupt the pituitary's ability to sense and suppress elevated T3 levels in advance of the periphery, producing symptoms of thyrotoxicity.


Key words: thyroid hormone receptors • corepressors • coactivators • TR • T3R

NURSA Molecule Pages Link:

Nuclear Receptors:   TRβ
Coregulators:   SRC-1  |  GRIP1  |  NCOR  |  SMRT
Ligands:   Thyroid hormone



This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
I. Jones, L. Ng, H. Liu, and D. Forrest
An Intron Control Region Differentially Regulates Expression of Thyroid Hormone Receptor {beta}2 in the Cochlea, Pituitary, and Cone Photoreceptors
Mol. Endocrinol., May 1, 2007; 21(5): 1108 - 1119.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society